comparemela.com

Zhujiang Hospital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nasal microbiota is potential diagnostic biomarker for sepsis

A new study shows that analyzing nasal microbiota outperforms gut microbiota analysis to predict sepsis in the ICU.

Groundbreaking artificial liver therapy approved for clinical trials in China

A stem cell-based bio-artificial liver therapy developed by scientists in China has received approval for clinical trials. Groundbreaking therapy system: The Chinese research team, led by Dr. Gao Yi from the Translational Medicine Centre at Zhujiang Hospital of Southern Medical University, developed the bio-artificial liver system that uses a bioreactor to perform the essential functions of the liver, such as detoxification and protein synthesis, outside the body. Deadly disease: Liver disease is responsible for 4% of all deaths, accounting for 2 million fatalities around the world each year.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.